Massimo Nicolò1, Davidina Ghiglione, Silvio Lai, Giovanni Calabria. 1. Dipartimento di Neuroscienze, Oftalmologia e Genetica, Sezione di Clinica Oculistica, Università di Genova, Osp. San Martino, Pad. 9, piano terra stanza 13. Largo R. Benzi 10, 16132, Genova, Italy. massimonicolo@occhioallaretina.it
Abstract
PURPOSE: To examine combined treatment of intravitreal triamcinolone acetonide (IVT) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). METHODS: Ten eyes of eight consecutive patients with RAP underwent a single injection (about 20 mg) of IVT followed 1 month later by PDT. Best-corrected visual acuity (BCVA) was measured by standardized protocol refraction. RESULTS: Median BCVA was 20/160, 20/64, 20/98, 20/89, 20/89, 20/125 at baseline and 1, 3, 6, 9 and 12 months, respectively. Of ten eyes, six (60%) improved BCVA of at least 3 lines at 1, 3, 6 and 9 months. Four (40%) eyes improved BCVA of at least 3 lines at 12 months. Three eyes (30%) lost >3 lines at 12 months. In all patients intraocular pressure was well controlled. No endophthalmitis, retinal detachment or vitreous haemorrhage developed. CONCLUSIONS: Improvement of BCVA suggests that combination treatment with IVT and PDT for RAP merits further investigation.
PURPOSE: To examine combined treatment of intravitreal triamcinolone acetonide (IVT) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). METHODS: Ten eyes of eight consecutive patients with RAP underwent a single injection (about 20 mg) of IVT followed 1 month later by PDT. Best-corrected visual acuity (BCVA) was measured by standardized protocol refraction. RESULTS: Median BCVA was 20/160, 20/64, 20/98, 20/89, 20/89, 20/125 at baseline and 1, 3, 6, 9 and 12 months, respectively. Of ten eyes, six (60%) improved BCVA of at least 3 lines at 1, 3, 6 and 9 months. Four (40%) eyes improved BCVA of at least 3 lines at 12 months. Three eyes (30%) lost >3 lines at 12 months. In all patients intraocular pressure was well controlled. No endophthalmitis, retinal detachment or vitreous haemorrhage developed. CONCLUSIONS: Improvement of BCVA suggests that combination treatment with IVT and PDT for RAP merits further investigation.
Authors: L A Yannuzzi; S Negrão; T Iida; C Carvalho; H Rodriguez-Coleman; J Slakter; K B Freund; J Sorenson; D Orlock; N Borodoker Journal: Retina Date: 2001 Impact factor: 4.256
Authors: Rogério A Costa; Daniela Calucci; Letícia Paccola; Rodrigo Jorge; José A Cardillo; Jarbas C Castro; Ingrid U Scott Journal: Am J Ophthalmol Date: 2005-07 Impact factor: 5.258
Authors: Jost B Jonas; Ulrich H Spandau; Björn Harder; Urs Vossmerbaeumer; Bernd A Kamppeter Journal: Am J Ophthalmol Date: 2005-06 Impact factor: 5.258
Authors: Ulrich H M Spandau; Mathias Derse; Paul Schmitz-Valckenberg; Christos Papoulis; Bernd-Udo Sagstetter; Karlheinz Stiefvater; Jost B Jonas Journal: Am J Ophthalmol Date: 2005-04 Impact factor: 5.258
Authors: Rufino M Silva; M Luz Cachulo; João Figueira; José R Faria de Abreu; J G Cunha-Vaz Journal: Graefes Arch Clin Exp Ophthalmol Date: 2007-08 Impact factor: 3.535